GLP-1 / GIP dual agonist as well as preparation method and application thereof
Modified GLP-1/GIP dual agonist compounds address the limitations of current treatments by extending half-life and minimizing side effects, offering safer and more convenient therapy for type II diabetes.
Patent Information
- Application Number
- CN202411031207.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-18
- Filing Date
- 2023-07-12
- Publication Date
- 2024-12-06
Smart Images

Figure CN119080887A_ABST
Abstract
Description
[0001] This application is a divisional application of application number 202310851003.5 filed on July 12, 2023, and entitled “GLP-1 / GIP dual agonists, preparation methods and uses thereof”. Technical Field
[0002] The present invention belongs to the field of medicine, and in particular relates to a GLP-1 / GIP dual agonist and use thereof in preparing a medicine for treating diabetes. Background Art
[0003] Type II diabetes is a chronic metabolic disease with high blood sugar as its clinical feature caused by insulin resistance. Elevated blood sugar can increase the incidence and mortality of various other diseases. Currently common treatments such as increased exercise, diet control, oral hypoglycemic drugs, and injections of therapeutic drugs can only temporarily maintain blood sugar balance, and cannot fundamentally treat diabetes and the many complex complications caused by high blood sugar. Therefore, it is of great clinical significance to actively explore and develop diabetes treatment drugs with new hypoglycemic mechanisms and high safety.
[0004] Glucagon-like peptide-1 (GLP-1) is a hormone mainly produced by intestinal L cells and belongs to the incretin category. GLP-1 is an important incretin hormone secreted by intestinal L cells. Its main physiological effects in the body include stimulating the secretion and release of insulin, inhibiting the secretion of glucagon, promoting the proliferation of pancreatic β cells and inhibiting their apoptosis, inhibiting gastric emptying, and promoting the production of satiety. Glucose-dependent insulinotropic polypeptide (GIP), which regulates blood sugar by promoting insulin and glucagon, has also been widely confirmed and applied.
[0005] Compounds with GLP-1 / GIP dual agonist activity have been described in WO2013164483A1, WO2014192284A1, WO2016111971A1.
[0006] Fatty acid modification of polypeptides can, for example, prolong the half-life through the physical binding motif of its fatty acid chain to the albumin subdomain, thereby improving the pharmacokinetics of the peptide. Although the use of fatty acids can improve the half-life of peptides, the specific effect of the extension and some side effects are still technical issues that need to be solved.
[0007] A series of side effects about GLP-1 include: For example, because animal studies and drug database analyses have shown that GLP-1 receptor agonists are associated with pancreatitis, pancreatic cancer, and thyroid cancer, there are concerns that these drugs will cause effects on pancreatic and thyroid tissue. Other case reports have linked the use of GLP-1 (mainly exenatide) to the occurrence of acute kidney injury, mainly due to hemodynamic disturbances caused by nausea, vomiting, and diarrhea. The most common symptoms associated with the use of GLP-1 receptor agonists are gastrointestinal symptoms, mainly nausea. Other common adverse reactions include injection site reactions, headaches, and nasopharyngitis. (Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1Receptor Agonists. Rev Diabet Stud. 2014Fall-Winter; 11(3-4):202-30.doi:10.1900 / RDS.2014.11.202.Epub 2015Feb 10.PMID:26177483; PMCID:PMC5397288.)
[0008] Side effects of tirzepatide (Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, T, Knop FK. The Effects of Dual GLP-1 / GIP Receptor Agonism on Glucagon Secretion-A Review. Int J Mol Sci. 2019 Aug 22; 20(17): 4092. doi: 10.3390 / ijms20174092. PMID: 31443356; PMCID: PMC6747202.): At the highest dose, tirzepatide had more adverse events than dulaglutide, especially gastrointestinal adverse events (66.0% of patients taking 15 mg tirzepatide and 42.6% of patients taking 1.5 mg dulaglutide), and also exceeded dulaglutide in the total number of hypoglycemic episodes (7.5% of participants taking 15 mg tirzepatide and 3.7% of participants taking dulaglutide) (Frias JP, Nauck MA, Van J., Kutner ME, Cui 2trial.Lancet.2018;392:2180–2193.doi:10.1016 / S0140-6736(18)32260-8.).To circumvent this problem, a titration strategy to reduce adverse events of tirzepatide has been reported (Frias J.P., Nauck MA, Van J., Benson C., Bray R., Milicevic Z., Haupt A., Robins D.A. 993-P: A 12-week, randomized, placebo-controlled study assessing the efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes. Diabetes. 2019; 68: 993. doi: 10.2337 / db19-993-P.), and the three-step dose-escalation regimen of 15 mg tirzepatide did not appear to be effective in reducing the overall incidence of gastrointestinal side effects compared with previously reported studies (Frias JP, Nauck MA, Van J., Kutner ME, Cui X., Benson C., Urva S., Gimeno R.E., Milicevic Z., Robins D., et al. Efficacy and safety of LY3298176, a noveldual GIP and GLP-1receptor agonist, in patients with type 2diabetes: arandomised, placebo-controlled and active comparator-controlled phase2trial. Lancet. 2018;392:2180–.
[0009] 2193.doi:10.1016 / S0140-6736(18)32260-8.). The incidence of hypoglycemic episodes also increased to ~16% in participants taking 15 mg of tilbotide. Although tilbotide treatment was still associated with promising weight loss (approximately 5.6 kg after 12 weeks), the high incidence of gastrointestinal side effects does bring some uncertainty to the clinical potential of tilbotide. In addition, the titration strategy in the marketing instructions for tilbotide is very time-consuming, with an initial dose of 2.5 mg, which is increased to 5 mg after 4 weeks. If the dose needs to be increased to control blood sugar, the current dose must be maintained for 4 weeks before increasing the dose by 2.5 mg, which is very inconvenient.
[0010] There is still a medical need to provide new compounds that are dual agonists of GIP and GLP-1 receptors and support the possibility of once-weekly dosing in humans, providing options with better safety, better efficacy, and more convenient medication. Summary of the invention
[0011] One object of the invention is to provide some long-acting GLP-1 / GIP dual agonist compounds. Compared with the GIP / GLP-1 dual agonist compounds in the art, the compounds of the present invention have a longer half-life and / or a more sustained duration of action. The compounds of the present invention have a stronger hypoglycemic effect. The compounds of the present invention have lower side effects, including but not limited to gastrointestinal reactions and cardiac safety risks. The compounds of the present invention can adopt a shorter titration strategy. The compounds of the present invention have a larger safety window. In addition, the compounds of the present invention have a protective effect on the liver.
[0012] As part of the present invention, applicants have discovered that the selection of the length, composition and attachment position of the fatty acid chain, as well as the linker between the peptide and the fatty acid chain, has an unexpected effect on extending the half-life of the polypeptide.
[0013] One embodiment of the present invention is to provide a compound of formula (AI) and a pharmaceutically acceptable salt thereof:
[0014] Y-X1-EGT-X2-TSDY-A11-A12-A13-LDK-A17-AQ-A20-EFVKWLLK-A29-GPSSGAPPPSK (AI);
[0015] wherein X1 is Aib; X2 is αMePhe;
[0016] A11 is Aib or Ala;
[0017] A12 is Ala, Ile, Lys, Phe or Pya (4);
[0018] A13 is Aib, Cha, Leu, αMePhe or αMeTyr;
[0019] A17 is Gln or Ile;
[0020] A20 is Ala or Ser;
[0021] A29 is Gln or Gly;
[0022] 1 K, 2 K, 3 K or 4 K positions are selected from the 16th, 24th, 28th and 40th positions by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 24, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester.
[0023] In another embodiment, the present invention provides a compound of formula (AI) or a pharmaceutically acceptable salt thereof, wherein,
[0024] X1 is Aib; X2 is αMePhe;
[0025] A11 is Aib or Ala;
[0026] A12 is Ala, Ile, Lys, Phe or Pya (4);
[0027] A13 is Aib, Cha, Leu, αMePhe or αMeTyr;
[0028] A17 is Gln or Ile;
[0029] A20 is Ala or Ser;
[0030] A29 is Gln or Gly,
[0031] 1 K, 2 K, 3 K or 4 K positions are selected from the 16th, 24th, 28th and 40th positions by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester; and compounds wherein c is independently selected from 14, 16, 18 or 20 are also provided.
[0032] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A11 is Aib; or / and
[0033] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A12 is Ile; or / and
[0034] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A13 is Aib; or / and
[0035] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A17 is Gln; or / and
[0036] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A20 is Ala; or / and
[0037] The peptide of the above formula (AI) or a pharmaceutically acceptable salt thereof, wherein A29 is Gly.
[0038] One embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0039] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0040] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; 1, 2, 3 or 4 K positions are selected from positions 16, 24, 28 and 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, each c is independently an integer from 10 to 24, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester; and the C-terminal amino acid is amidated to form a C-terminal primary amide.
[0041] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein one K position is selected from among the K at positions 16, 24, 28, and 40 by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain and chemically modified. For example, at the 16-position of K, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain; for example, at the 24-position of K, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a-(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain; for example, at position 28 of K, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain; for example, at position 40 of K, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain.
[0042] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the positions of 2 K are selected from among the 16-position, 24-position, 28-position, and 40-position K, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains. For example, at the positions of K at position 16 and K at position 24, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains; for example, at the positions of K at position 16 and K at position 28, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains; for example, at the positions of K at position 16 and K at position 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains; for example, at the positions of K at position 24 and K at position 28, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains; for example, at the positions of K at position 24 and K at position 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains; for example, at the positions of K 28 and K 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to perform chemical modification of the two modified chains.
[0043] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the positions of 3 K are selected from among the 16-position, 24-position, 28-position, and 40-position K by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of the three modified chains. For example, at the positions of K at position 16, K at position 24, and K at position 28, ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of the three modified chains; for example, at the positions of K at 16, K at 24, and K at 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of three modified chains; for example, at the positions of K 16, K 28 and K 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of the three modified chains; for example, at the positions of K at position 24, K at position 28, and K at position 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to perform chemical modification of the three modified chains.
[0044] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the positions of 4 K are selected from among the 16-position, 24-position, 28-position, and 40-position K by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is conjugated to the ε-amino group of the K side chain to carry out chemical modification of the four modified chains. For example, at the positions of K 16, K 24, K 28 and K 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z was conjugated to the ε-amino group of the K side chain to perform chemical modification of the four modified chains.
[0045] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester, for example, but not limited to, the Z may include carboxylic acid (-CO2H) or carboxylic acid bioisostere (e.g. ), phosphonic acid (-P(O)(OH)2) or sulfonic acid (-SO2OH) groups, preferably -CO2H.
[0046] Carboxylic acid bioisosteres, suitable carboxylic acid bioisosteres are known in the art. Preferably, the bioisostere has a pK a Protons similar to the corresponding carboxylic acids. Examples of suitable bioisosteres may include, but are not limited to, tetrazoles, acylsulfonamides, acylhydroxylamines, and squaric acid derivatives, as shown below:
[0047] R is Me or CF3.
[0048] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, preferably 1, 2 or 3, b is independently selected from an integer of 1, 2, 3, 4 or 5, preferably 1, 2 or 3, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0049] One embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0050] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0051] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; one or two K positions are selected from the 16th, 24th, 28th, and 40th positions by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester, preferably -CO2H, each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 24; and the C-terminal amino acid is amidated to form a C-terminal primary amide.
[0052] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; one or two K positions are selected from positions 16, 24, 28, and 40, by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester, preferably -CO2H, a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides compounds wherein c is 14, 16, 18 or 20.
[0053] One embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0054] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0055] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer from 0 to 5, b is independently selected from an integer from 0 to 5, and c is independently selected from an integer from 10 to 24; and the C-terminal amino acid is amidated to a C-terminal primary amide.
[0056] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0057] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0058] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0059] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer from 0 to 5, b is independently selected from an integer from 0 to 5, and c is independently selected from an integer from 10 to 24; and the C-terminal amino acid is amidated to a C-terminal primary amide.
[0060] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0061] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0062] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0063] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 16 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer from 0 to 5, b is independently selected from an integer from 0 to 5, and c is independently selected from an integer from 10 to 24; and the C-terminal amino acid is amidated to a C-terminal primary amide.
[0064] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 16 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0065] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0066] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0067] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer from 0 to 5, b is independently selected from an integer from 0 to 5, and c is independently selected from an integer from 10 to 24; and the C-terminal amino acid is amidated to a C-terminal primary amide.
[0068] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0069] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0070] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0071] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 24 and 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0072] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 24 and 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0073] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0074] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0075] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0076] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0077] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0078] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0079] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0080] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0081] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0082] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0083] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0084] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 16 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0085] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0086] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0087] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 24 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0088] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 24 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0089] Another embodiment of the present invention is to provide a compound of formula (I) and a pharmaceutically acceptable salt thereof:
[0090] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK formula (I);
[0091] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 28 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain to perform chemical modification of two modified chains, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; and the C-terminal amino acid is amidated to become a C-terminal primary amide.
[0092] In another embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at positions 28 and 40 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-CO2H is conjugated to the ε-amino group of the K side chain to carry out chemical modification of two modified chains, wherein a is independently selected from an integer of 1, 2, 3, 4 or 5, b is independently selected from an integer of 1, 2, 3, 4 or 5, and c is independently selected from an integer of 12 to 22; in addition, the present invention provides a compound wherein c is 14, 16, 18 or 20.
[0093] In all the embodiments described above, each a is independently an integer from 1 to 3, each b is independently an integer from 1 to 3, and each c is independently an integer from 12 to 22; in addition, the present invention provides compounds wherein c is 14, 16, 18 or 20. In all the embodiments described above, it is preferred that a modification of a modified chain is performed on K at position 24 or 28.
[0094] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0095] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0096] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 7).
[0097] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0098] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0099] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 18 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 13).
[0100] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0101] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0102] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 14).
[0103] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0104] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0105] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain for chemical modification; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 15).
[0106] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0107] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0108] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20-CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 16).
[0109] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0110] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0111] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 8).
[0112] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0113] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0114] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 17).
[0115] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0116] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0117] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 18).
[0118] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0119] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0120] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 19).
[0121] In one embodiment, the present invention provides a compound of the formula or a pharmaceutically acceptable salt thereof:
[0122] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0123] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 20).
[0124] The present invention also provides a method for increasing the duration of action of a GLP-1 / GIP dual agonist in a patient, characterized in that the method comprises using the acylated GLP-1 / GIP dual agonist provided by the present invention as described above.
[0125] In one embodiment, the present invention provides a composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent or excipient.
[0126] One embodiment provides the use of a compound according to any one of the above embodiments in the preparation of a medicament for treating or preventing the following diseases: hyperglycemia, impaired glucose tolerance, type I diabetes, type II diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease and other cardiovascular diseases, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcer.
[0127] One embodiment provides the use of a compound according to any one of the above embodiments for the preparation of a medicament for delaying or preventing the disease progression of type II diabetes.
[0128] One embodiment provides the use of a compound according to any one of the above embodiments for the preparation of a medicament for reducing food intake, reducing β-cell apoptosis, increasing β-cell function and β-cell mass and / or restoring glucose sensitivity of β-cells.
[0129] In one embodiment, the present invention provides a method of treating type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
[0130] In one embodiment, the present invention provides a method of improving glycemic control in a patient with type 2 diabetes comprising administering to a patient in need thereof an effective amount of a compound of the present invention as an adjunct to diet and exercise.
[0131] In one embodiment, the present invention provides a method for long-term weight management in a patient with an initial body mass index ≥ 27 and type 2 diabetes, comprising administering to a patient in need thereof an effective amount of a compound of the present invention as an adjunct to a reduced calorie diet and increased physical activity.
[0132] In one embodiment, the present invention provides a method for treating metabolic syndrome, comprising administering an effective amount of a compound of the present invention to a patient in need thereof. In another embodiment, the present invention provides a method for treating dyslipidemia, obesity and / or hepatic steatosis associated with insulin resistance and diabetes, comprising administering an effective amount of a compound of the present invention to a patient in need thereof. In addition, the present invention provides a method for treating weakness or increasing bone strength, comprising administering an effective amount of a compound of the present invention to a patient in need thereof.
[0133] In one embodiment, the present invention provides compounds of the present invention for use as an adjunct to diet and exercise for glycemic control in patients with type II diabetes. In one embodiment, the present invention provides compounds of the present invention for use as an adjunct to a hypocaloric diet and increased physical activity in patients with an initial body mass index ≥ 27 and type II diabetes for long-term weight management.
[0134] The compounds of the present invention can be used as drugs for treating or preventing various diseases, including obesity, due to the above-mentioned activation of GLP-1 receptors and GIP receptors. The compounds of the present invention can be used as drugs for preventing or treating the following diseases: for example, symptomatic obesity, obesity based on simple obesity, disease states or diseases related to obesity, eating disorders, diabetes (for example, type I diabetes, type II diabetes, gestational diabetes, obesity-related diabetes), hyperlipidemia (for example, hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterolemia, low HDL-cholesterolemia, postprandial hyperlipidemia), hypertension, heart failure, complications of diabetes [for example, neuropathy, nephropathy, Retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious diseases (e.g., respiratory tract infection, urinary tract infection, gastrointestinal infection, superficial soft tissue infection, lower limb infection), diabetic gangrene, xerostomia, hearing loss, cerebrovascular disorders, peripheral blood circulation disorders, metabolic syndrome (a disease state having three or more selected from hypertriglyceridemia (TG), low HDL cholesterolemia (HDL-C), hypertension, abdominal obesity and impaired glucose tolerance), sarcopenia, and the like.
[0135] Examples of symptomatic obesity include endocrine obesity (e.g., Cushing's syndrome, hypothyroidism, insulinoma, obese type II diabetes, pseudohypoparathyroidism, hypogonadism), central obesity (e.g., hypothalamic obesity, frontal lobe syndrome, Klebsiella pneumoniae syndrome), genetic obesity (e.g., Prader-Willi syndrome, Law-Moon-Biedl syndrome), drug-induced obesity (e.g., obesity induced by steroids, phenothiazines, insulin, sulfonylurea (SU) drugs, beta-blockers), and the like.
[0136] Examples of disease states or diseases associated with obesity include: glucose tolerance disorders, diabetes (especially type II diabetes, obese diabetes), abnormal lipid metabolism (synonymous with the above-mentioned hyperlipidemia), hypertension, heart failure, hyperuricemia, fatty liver (including non-alcoholic hepatitis), coronary heart disease (myocardial infarction, angina pectoris), cerebral infarction (cerebral thrombosis, transient ischemic attack), bone / joint diseases (osteoarthritis of the knee, osteoarthritis of the hip, deformed spondylitis, low back pain), sleep apnea syndrome / Pickwick syndrome, menstrual disorders (abnormal menstrual cycle, amenorrhea, abnormal menstrual symptoms), metabolic syndrome, etc.
[0137] The compound provided by the present invention has GLP-1 / GIP dual agonist activity, a long half-life, and shows a longer duration of drug effect.
[0138] The compounds of the present invention can react with any of a variety of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Pharmaceutically acceptable salts and common methods for preparing them are well known in the art.
[0139] The amino acid sequences of the present invention contain the standard single-letter or three-letter codes for the twenty natural amino acids. In addition, "Aib" is α-aminoisobutyric acid, "αMePhe" is α-methylphenylalanine, "Pya(4)" is 4-pyridylalanine, "Cha" is cyclohexylalanine, and "αMeTyr" is α-methyltyrosine.
[0140] The "AEEA" of the present invention is the abbreviation of 2-(2-amino-ethoxy)-ethoxy]-acetyl. The "Ste" of the present invention represents octadecane dioic acid-C(O)-C 16 H 32 -C(O)-.
[0141] The "effective amount" or "therapeutically effective amount" of the present invention is the amount or dosage of the compound of the present invention or its pharmaceutically acceptable salt, which, when administered to a patient in single or multiple doses, provides the desired effect in the patient being diagnosed or treated.
[0142] The "effective dose" of the present invention refers to the minimum dose that has a pharmacological effect. Specifically, in the db / db mouse multiple drug administration efficacy experiment of the present invention, it refers to the minimum dose at which the blood glucose AUC of the test substance administration group has a significant difference (P<0.05) compared with the vehicle group.
[0143] The "Efficacy Dose" of the present invention refers to the dosage with a pharmacological effect. Specifically, in the db / db mouse multiple administration efficacy experiment of the present invention, it refers to the dosage at which the blood glucose AUC of the test substance administration group has a significant difference (P<0.05) compared with the vehicle group.
[0144] The "Vehicle group" described in the present invention refers to the vehicle control group.
[0145] The "AUC" mentioned in the present invention refers to the area under the drug-time curve, that is, the area enclosed by the drug concentration curve on the time axis. This parameter is an important indicator for evaluating the degree of drug absorption and reflects the exposure characteristics of the drug in the body.
[0146] The "MRT" mentioned in the present invention refers to the mean residence time, which is the average of the residence time of drug molecules in the body, indicating the time required to eliminate 63.2% of the drug from the body.
[0147] The "MTD" mentioned in the present invention refers to the maximum tolerated dose, which is the highest dose that does not cause the death of the test animals.
[0148] The "internal standard" mentioned in the present invention refers to a known amount of a pure compound added to a sample to correct errors caused by instrument signal fluctuations, human operation, etc.
[0149] The "blood glucose AUC inhibition rate" of the present invention is the percentage of blood glucose AUC reduction in the test substance administration group compared with the vehicle group. Blood glucose AUC inhibition rate = (blood glucose AUC Vehicle - Blood glucose AUC 受试物 ) / blood glucose AUC Vehicle
[0150] The "titration strategy" described in the present invention is a method of increasing the dose, that is, after the initial dose, the frequency of increasing the dose and the dosage are adjusted to obtain the optimal dosage.
[0151] The "patient" described in the present invention includes humans or animals, preferably humans.
[0152] The "modified chain" described in the present invention is ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c-Z, wherein each a is independently an integer from 0 to 5, each b is independently an integer from 0 to 5, and each c is independently an integer from 10 to 22; further wherein a is independently an integer selected from 1, 2, 3, 4 or 5, b is independently an integer selected from 1, 2, 3, 4 or 5, and c is independently an integer selected from 12 to 22; in addition, the present invention provides compounds wherein c is 14, 16, 18 or 20, wherein Z is independently selected from -CH3, carboxylic acid or carboxylic acid bioisostere, phosphonate / ester or sulfonate / ester, for example, but not limited to, the Z may include carboxylic acid (-CO2H) or carboxylic acid bioisostere (e.g. ), phosphonic acid (-P(O)(OH)2) or sulfonic acid (-SO2OH) groups, preferably -CO2H.
[0153] Carboxylic acid bioisosteres, suitable carboxylic acid bioisosteres are known in the art. Preferably, the bioisostere has a pK a Protons similar to the corresponding carboxylic acids. Examples of suitable bioisosteres may include, but are not limited to, tetrazoles, acylsulfonamides, acylhydroxylamines, and squaric acid derivatives, as shown below:
[0154] R is Me or CF3.
[0155] For the peptides mentioned herein, according to conventional peptide notation, the left end is the N-terminus (amino terminus) and the right end is the C-terminus (carboxyl terminus). The C-terminus of the peptide can be an amide (-CONH2), a carboxyl group (-COOH), a carboxylate group (-COO - ), any of alkylamides (-CONHR') and esters (-COOR'), R' is C 1-8 An alkyl group. In particular, an amide (-CONH2) is preferred.
[0156] The "coupling" or "accession" in the preparation method of the present invention refers to the process of adding new amino acids to the combined amino acids or peptides. BRIEF DESCRIPTION OF THE DRAWINGS
[0157] Figure 1A-1B Shown are changes in blood glucose in db / db mice after administration. Figure 1A Shown are the changes in blood glucose in db / db mice after a single subcutaneous administration of 10 nmol / kg of P007, P008, P014, P019, Tirzepatide, and P001; Figure 1B Shown are the changes in blood glucose in db / db mice after a single subcutaneous administration of P013, P015, P016, P017, P018, P020 and Tirzepatide 10 nmol / kg.
[0158] Figures 2A-2CThe blood glucose AUC after dosing in db / db mice is shown. Figure 2A The AUC of P007, P008, P014, P019, Tirzepatide, and P001 from 0 to 48 h after a single subcutaneous dose of 10 nmol / kg is shown; Figure 2B The AUC of P007, P008, P014, P019 and Tirzepatide 10 nmol / kg after a single subcutaneous dose from 0 to 72 h are shown; Figure 2C Shown are the 0-56h AUCs of P013, P015, P016, P017, P018, P020 and Tirzepatide after a single subcutaneous dose of 10 nmol / kg. Figure 2A Medium T-Test, *p<0.05, **p<0.01, ***p<0.001 compared with Vehicle; §p<0.05, §§p<0.01, §§§p<0.001 compared with P001. Figure 2B Medium T-Test, *p<0.05, **p<0.01, ***p<0.001 compared with Vehicle; #p<0.05, ##p<0.01 compared with Tirzepatide. Figure 2C Medium T-Test, *p<0.05, **p<0.01, ***p<0.001 compared with Vehicle; #p<0.05 compared with Tirzepatide.
[0159] Figures 3A-3D Shown are changes in blood glucose in db / db mice after multiple administrations. Figure 3A The changes in blood glucose in db / db mice after multiple subcutaneous administration of P014 and Tirzepatide were compared; Figure 3B The changes in blood glucose in db / db mice after multiple subcutaneous administration of P016 and Tirzepatide were compared; Figure 3C The changes in blood glucose in db / db mice after multiple subcutaneous administration of P017 and Tirzepatide were compared; Figure 3D The changes in blood glucose in db / db mice were compared after multiple subcutaneous administration of P020 and Tirzepatide.
[0160] The present invention also includes novel intermediates and methods that can be used to synthesize the compounds of the present invention or their pharmaceutically acceptable salts. The intermediates and compounds of the present invention can be prepared by a variety of methods known in the art. In particular, methods using chemical synthesis are illustrated in the following examples. The specific synthetic steps of each described approach can be combined in different ways to prepare the compounds of the present invention or their salts. Reagents and raw materials are readily available to those of ordinary skill in the art. It should be understood that these examples are not intended to limit the scope of the present invention in any way. The mass spectrometer uses an Agilent 1260 / 6110 liquid chromatograph-mass spectrometer with a scan range of 100-1500.
[0161] Embodiment 1:
[0162] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0163] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain for chemical modification; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 15).
[0164]
[0165] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K24, for which the structure has been unfolded.
[0166] The preparation method adopts the Fmoc solid phase peptide synthesis strategy, and the method includes:
[0167] (1) Synthesis of peptide resin intermediate 1
[0168] Take Fmoc-Rink Linker-Nle-MBHA resin (S = 0.49 mmol / g), swell it with an appropriate amount of DCM, and wash it with DCM 2-3 times. Deprotect it with 20% PIP / DMF solution for 30 minutes, filter and wash it to obtain the Fmoc-free NH2-Rink linker-Nle-MBHA resin, and drain the solvent for use.
[0169] Take 4 equivalents of Fmoc-Lys(Boc)-OH and HOBt respectively, dissolve them in appropriate amount of DMF / DCM; take another 4 equivalents of DIC, dilute it by half with DCM, slowly add it to the DMF / DMC solution under stirring, stir and react at -5~0℃ for not less than 60 minutes, and set aside after activation.
[0170] Add the activated Fmoc-Lys(Boc)-OH solution to the NH2-Rink linker–Nle-MBHA resin, control the reaction temperature at 10-30°C, carry out the coupling reaction for 240-480 min, filter and wash to obtain the Fmoc-Lys(Boc)-Rink linker–Nle-MBHA resin, deprotect with 20% PIP / DMF solution for 30 min, filter and wash to obtain the de-Fmoc Lys(Boc)-Rinklinker–Nle-MBHA resin.
[0171] Similarly, the reaction conditions were followed, starting from the second amino acid at the C-terminus and coupled to the N-terminus one by one. If the coupling was incomplete (color reaction), a second condensation was performed using HBTU / DIEA to ensure that each amino acid was completely condensed. The coupling sequence is Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH.H2O, Fmoc-Gly-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Gly- Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH.H2O, Fmoc-Ala-OH.H2O , Fmoc-Gln(Trt)-OH, Fmoc-Ala-OH.H2O, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Aib-OH, Fmoc-Ile-OH, Fmoc-Aib-OH, Fmoc-Tyr( tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-α-Me-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Glu(OtBu)-Gly-OH, Fmoc-Aib-OH, Boc-Tyr(tBu)-OH.
[0172] get:
[0173] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala-Gln (Trt)-Ala-Glu(OtBu)-Phe-Val-Lys(Mtt)-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink Linker-Nle-MBHA Resin
[0174] After the above condensation is complete, the Mtt protection is removed with 50% HFIP / DCM solution for 30 minutes, followed by washing and filtration to obtain the peptide resin intermediate 1:
[0175] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala- Gln(Trt)-Ala-Glu(OtBu)-Phe-Val-Lys-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink Linker-Nle-MBHA Resin.
[0176] (2) Modification chain modification step
[0177] Take 4 equivalents of Fmoc-AEEA-OH and HOBt and dissolve them in appropriate amount of DMF / DCM; take another 4 equivalents of DIC, dilute it by half with DCM, slowly add it to the DMF / DCM solution with stirring, stir the reaction at -5 to 0°C for not less than 60 minutes, and set aside after activation.
[0178] The activated Fmoc-AEEA-OH solution was added to the previously swollen and washed peptide resin intermediate 1, the reaction temperature was controlled at 10-30°C, the coupling reaction was carried out for 240-480 minutes, filtered and washed, and Fmoc protection was removed with 20% PIP / DMF solution for 30 minutes, filtered and washed. According to the above reaction conditions, the activated Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu(α-OtBu)-OH, Fmoc-Glu(α-OtBu)-OH, Fmoc-Glu(α-OtBu)-OH and octadecane dioic acid mono-tert-butyl ester were coupled on the resin in turn, Fmoc was deprotected, washed with DCM and dried to obtain P015 peptide resin:
[0179] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala-G ln(Trt)-Ala-Glu(OtBu)-Phe-Val-Lys(tBuO-Ste-γ-Glu(α-OtBu)-γ-Glu(α-OtBu)-γ-Glu(α-OtBu)-AEEA-AEEA)-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-
[0180] Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink-Linker-Nle-MBHA Resin.
[0181] Take P 015 peptide resin, add 12-15mL / g peptide resin cleavage agent (TFA:EDT:TIS:H2O, volume ratio 94:2:2:2), stir and react at 25±5℃ for 4 hours, filter the reaction mixture using a sand core funnel, collect the filtrate, wash the resin with a small amount of TFA 3 times, combine the filtrates and concentrate under reduced pressure, add methyl tert-butyl ether (MBTE) to precipitate, wash with MBTE 3-4 times, evaporate MTBE, and dry the crude product under reduced pressure at room temperature to constant weight to obtain P015 crude product, which is subsequently purified and dried to obtain a P015 sample (mass spectrum MS: 5255.2).
[0182] Embodiment 2:
[0183] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0184] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 19).
[0185]
[0186] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K28, for which the structure has been unfolded.
[0187] The preparation method adopts the Fmoc solid phase peptide synthesis strategy, and the method includes:
[0188] (1) Synthesis of peptide resin intermediate 2
[0189] Take Fmoc-Rink Linker-Nle-MBHA resin (S=0.49mmol / g), swell it with an appropriate amount of DCM, and wash it with DCM 2-3 times. Deprotect it with 20% PIP / DMF solution for 30 minutes, wash and filter to obtain the Fmoc-free NH2-Rink linker-Nle-MBHA resin, and drain the solvent for use.
[0190] Take 4 equivalents of Fmoc-Lys(Boc)-OH and HOBt respectively, dissolve them in appropriate amount of DMF / DCM; take another 4 equivalents of DIC, dilute it by half with DCM, slowly add it to the DMF / DMC solution under stirring, stir and react at -5~0℃ for not less than 60 minutes, and set aside after activation.
[0191] Add the activated Fmoc-Lys(Boc)-OH solution to the NH2-Rink linker–Nle-MBHA resin, control the reaction temperature at 10-30°C, carry out the coupling reaction for 240-480 min, filter and wash to obtain the Fmoc-Lys(Boc)-Rink linker–Nle-MBHA resin, deprotect with 20% PIP / DMF solution for 30 min, filter and wash to obtain the de-Fmoc Lys(Boc)-Rinklinker–Nle-MBHA resin.
[0192] Similarly, the reaction conditions were followed, starting from the second amino acid at the C-terminus and coupled to the N-terminus one by one. If the coupling was incomplete (color reaction), a second condensation was performed using HBTU / DIEA to ensure that each amino acid was completely condensed. The coupling sequence is Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH.H2O, Fmoc-Gly-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Gly- Gly-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH.H2O, Fmoc-Ala-OH.H2O , Fmoc-Gln(Trt)-OH, Fmoc-Ala-OH.H2O, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Aib-OH, Fmoc-Ile-OH, Fmoc-Aib-OH, Fmoc-Tyr( tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-α-Me-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Glu(OtBu)-Gly-OH, Fmoc-Aib-OH, Boc-Tyr(tBu)-OH.
[0193] get:
[0194] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala-Gln (Trt)-Ala-Glu(OtBu)-Phe-Val-Lys(Boc)-Trp(Boc)-Leu-Leu-Lys(Mtt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink Linker-Nle-MBHA Resin
[0195] After the above condensation is complete, the Mtt protection is removed with 50% HFIP / DCM solution for 30 minutes, followed by washing and filtration to obtain the peptide resin intermediate 2:
[0196] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala- Gln(Trt)-Ala-Glu(OtBu)-Phe-Val-Lys(Boc)-Trp(Boc)-Leu-Leu-Lys-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink Linker-Nle-MBHA Resin.
[0197] (2) Modification chain modification step
[0198] Take 4 equivalents of Fmoc-AEEA-OH and HOBt and dissolve them in appropriate amount of DMF / DCM; take another 4 equivalents of DIC, dilute it by half with DCM, slowly add it to the DMF / DCM solution with stirring, stir the reaction at -5 to 0°C for not less than 60 minutes, and set aside after activation.
[0199] The activated Fmoc-AEEA-OH solution was added to the previously swollen and washed peptide resin intermediate 2, the reaction temperature was controlled at 10-30°C, the coupling reaction was carried out for 240-480 minutes, filtered and washed, and Fmoc protection was removed with 20% PIP / DMF solution for 30 minutes, filtered and washed. According to the above reaction conditions, the activated Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu)-OH and octadecane dioic acid mono-tert-butyl ester were coupled on the resin in turn, Fmoc was deprotected, washed with DCM and dried to obtain P019 peptide resin:
[0200] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(t Bu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala-Gln(Trt)-Ala-Glu(OtBu)-Phe-V al-Lys(tBuO-Ste-γ-Glu(α-OtBu)-AEEA-AEEA-AEEA)-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink-Linker-Nle-MBHA Resin.
[0201] Take P 019 peptide resin, add 12-15mL / g peptide resin cleavage agent (TFA:EDT:TIS:H2O, volume ratio 94:2:2:2), stir and react at 25±5℃ for 4 hours, filter the reaction mixture using a sand core funnel, collect the filtrate, wash the resin with a small amount of TFA 3 times, combine the filtrates and concentrate under reduced pressure, add methyl tert-butyl ether (MBTE) to precipitate, wash with MBTE 3-4 times, evaporate MTBE, and dry the crude product under reduced pressure at room temperature to constant weight to obtain P019 crude product, which is subsequently purified and dried to obtain a P019 sample (mass spectrum MS: 5142.0).
[0202] Example 3
[0203] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0204] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 7).
[0205]
[0206] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K24, for which the structure has been unfolded.
[0207] Similar to the above Example 1, peptide resin intermediate 1 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 7 of the present invention (mass spectrum MS: 4997.2). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu)-OH and octadecane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P007 peptide resin, and the other steps are similar.
[0208] Embodiment 4:
[0209] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0210] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 18 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 13).
[0211]
[0212] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K24, for which the structure has been unfolded.
[0213] Similar to the above Example 1, peptide resin intermediate 1 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 13 of the present invention (mass spectrum MS: 5025.2). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu) -OH and mono-tert-butyl eicosandioate on the resin, deprotect Fmoc, wash with DCM and dry to obtain P013 peptide resin, and the other steps are similar.
[0214] Embodiment 5:
[0215] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0216] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 14).
[0217]
[0218] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K24, for which the structure has been unfolded.
[0219] Similar to the above Example 1, peptide resin intermediate 1 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 14 of the present invention (mass spectrum MS: 5052.4). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu) -OH and docosane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P014 peptide resin, and the other steps are similar.
[0220] Embodiment 6:
[0221] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0222] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 24 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 16).
[0223]
[0224] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K24, for which the structure has been unfolded.
[0225] Similar to the above Example 1, peptide resin intermediate 1 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 16 of the present invention (mass spectrum MS: 5198.0). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu)-OH and docosanediolatoic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P016 peptide resin, and the other steps are similar.
[0226] Embodiment 7:
[0227] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0228] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 8).
[0229]
[0230] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K28, for which the structure has been unfolded.
[0231] Similar to the above Example 2, peptide resin intermediate 2 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 8 of the present invention (mass spectrum MS: 4996.8). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu) -OH and octadecane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P008 peptide resin, and the other steps are similar.
[0232] Embodiment 8:
[0233] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0234] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 17).
[0235]
[0236] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K28, for which the structure has been unfolded.
[0237] Similar to the above Example 2, peptide resin intermediate 2 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 17 of the present invention (mass spectrum MS: 5052.8). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu)-OH and docosane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P017 peptide resin, and the other steps are similar.
[0238] Embodiment 9:
[0239] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0240] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 18).
[0241]
[0242] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K28, for which the structure has been unfolded.
[0243] Similar to the above Example 2, peptide resin intermediate 2 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 18 of the present invention (mass spectrum MS: 5255.2). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu(α-OtBu)-OH, Fmoc-Glu(α-OtBu)-OH, Fmoc-Glu(α-OtBu)-OH and octadecane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P018 peptide resin, and the other steps are similar.
[0244] Embodiment 10:
[0245] Y-X1-EGT-X2-TSDY-X3-I-X4-LDKQAQAEFVKWLLKGGPSSG-APPPSK;
[0246] wherein X1 is Aib; X2 is αMePhe; X3 is Aib; X4 is Aib; K at position 28 is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 20).
[0247]
[0248] The above structure contains the standard single letter amino acid code except for residues Aib2, αMePhe6, Aib11, Aib13 and K28, for which the structure has been unfolded.
[0249] Similar to the above Example 2, peptide resin intermediate 2 was used to carry out the preparation steps to synthesize the peptide of SEQ ID NO: 20 of the present invention (mass spectrum MS: 5198.4). The difference is that the modification process of the modified chain is to sequentially couple Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-AEEA-OH, Fmoc-Glu (α-OtBu)-OH and docosane dioic acid mono-tert-butyl ester on the resin, deprotect Fmoc, wash with DCM and dry to obtain P020 peptide resin, and the other steps are similar.
[0250] In some embodiments of the present invention, peptide resin intermediate 3 is prepared by the method for preparing peptide resin intermediate 1 in reference example 1 to obtain peptide resin intermediate 3 (peptide resin intermediate with modified chain at position 16 Lys):
[0251] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys-Gln(Trt)-Ala-Gln(T rt)-Ala-Glu(OtBu)-Phe-Val-Lys(Boc)-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys(Boc)-Rink Linker-Nle-MBHA Resin
[0252] Peptide resin intermediate 4, peptide resin intermediate 4 (peptide resin intermediate with modified chain at position 40 Lys) was obtained by referring to the preparation method of peptide resin intermediate 1 in Example 1:
[0253] Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-αMePhe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Aib-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-Gln(Trt)-Ala- Gln(Trt)-Ala-Glu(OtBu)-Phe-Val-Lys(Boc)-Trp(Boc)-Leu-Leu-Lys(Boc)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Lys-Rink Linker-Nle-MBHAResin
[0254] Other dual agonist compounds in the present invention can be prepared by referring to the above method.
[0255] Related assays
[0256] The conditions and data used in the examples for several assays are provided below.
[0257] 1. In vitro function
[0258] (I) In vitro binding activity to human GLP-1 and GIP receptors
[0259] The in vitro binding potency of the compounds of the present invention to human GIP and GLP-1 receptors was evaluated by measuring the binding affinity Ki using crude cell membranes obtained from cloned cell lines overexpressing human GLP-1R cDNA or human GIP-R cDNA.
[0260] 1) In vitro binding activity to human GLP-1 receptor
[0261] hGLP-1 and the compounds of the present invention were dissolved in DMSO and stored at -80°C. 89 μL of membrane (5 μg / well) dissolved in binding buffer (50 mM Hepes, pH 7.4, 5 mM MgCl2, 5 mM EDTA, 0.005% TWEEN, 0.005% HSA) was transferred to a 96-well assay plate. The compounds were serially diluted in DMSO, and then 1 μL of the diluted compound or 100% DMSO was added to the assay plate containing the membrane solution. 10 μL of [ 125 I] GLP-1 (final reaction concentration 0.15nM). The test plate was placed at room temperature for 90 minutes. The membrane complex was collected into a 0.5% PEI pre-coated GF / B plate using Cell Harvester and rinsed three times with 500μL of 4°C pre-cooled elution buffer (50mM Hepes, pH 7.4, 500mM NaCl). After drying at 37°C for 2 hours, 50μL of scintillation fluid was added to each well, sealed and left for at least 1 hour. The reading was then performed using Microbet2 to determine the level of membrane-bound radioligand.
[0262] pass[ 125 I] Nonlinear regression of the percentage of GLP-1 binding and the concentration of added compound was used to obtain the absolute IC 50 The Cheng-Prusoff formula is used to convert IC 50 The concentrations were converted to Ki (Ki is the inhibition constant).
[0263] 2) In vitro binding activity to human GIP receptor
[0264] hGIP and compounds of the invention were dissolved in DMSO and stored at -80°C. 98 μL of membrane (15 μg / well) dissolved in binding buffer (50 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.1% BSA, 0.005% Tween-20) was transferred to a 96-well assay plate. Compounds were serially diluted in DMSO, and then 2 μL of diluted compounds or 100% DMSO was added to the assay plate containing the membrane solution. 100 μL of [ 125I] GIP (final reaction concentration 0.0315nM). The test plate was placed at room temperature for 90 minutes. The membrane complex was collected into 0.5% PEI pre-coated GF / B plate using Cell Harvester and rinsed three times with 500μL of 4°C pre-cooled elution buffer (50mM Tris-HCl pH 7.4, 125mM NaCl). After drying at 37°C for 2 hours, 50μL of scintillation fluid was added to each well, sealed and placed for at least 1 hour. Then read with Microbeta2 to determine the level of membrane-bound radioligand.
[0265] pass[ 125 The absolute IC was obtained by nonlinear regression of the percentage of GIP binding and the concentration of the added compound. 50 The Cheng-Prusoff formula is used to convert IC 50 The concentrations were converted to Ki (Ki is the inhibition constant).
[0266] Table 1. Receptor binding affinities, Ki ratios
[0267]
[0268] NA: Not detected
[0269] Ki ratio: the ratio of the Ki value of the endogenous ligand to the Ki value of the test compound
[0270] The binding affinity of all compounds to receptors is expressed as Ki ratio, and the larger the Ki ratio, the stronger the binding affinity of the compound. Compared with P001, the binding affinity of the compounds of the present invention to human GLP-1R and GIPR is decreased to a certain extent (see Table 1).
[0271] Compared with Tirzepatide, except for P015, the binding affinity of the other nine compounds of the present invention to human GLP-1R is slightly stronger than that of Tirzepatide, and among them, the binding affinity of five compounds, P008, P013, P014, P016 and P019, to GIPR is also slightly stronger than that of Tirzepatide (see Table 1).
[0272] In summary, the compounds of the present invention with different forms of modified chains have a binding affinity to human GLP-1R and GIPR that is somewhat lower than that of P001, but is slightly stronger than or equivalent to that of Tirzepatide.
[0273] (II) Agonist activity on hGLP-1R and hGIPR
[0274] For human GLP-1 and GIP receptors, the in vitro functional activity of the compounds of the invention at these receptors was determined in HEK-293 clonal cell lines expressing these receptors.
[0275] 1) Agonist activity on human GLP-1 receptor (cAMP reporter gene method)
[0276] The cAMP reporter gene method was used to determine the agonist activity of the compounds of the present invention on human GLP-1R, with P001, Tirzepatide and endogenous ligand GLP-1 as references.
[0277] HEK293 / CRE / GLP-1R cells were seeded in 96-well plates at 50,000 cells / well (80 μL / well) and cultured overnight in a 37°C, 5% CO2 incubator. 20 μL / well of assay medium (DMEM containing 0.1% casein) containing compounds (compounds of the present invention, P001, Tirzepatide or GLP-1) was added to the 96-well plate and incubated in a 37°C CO2 incubator for 6 hours, equilibrated to room temperature, the supernatant was removed, 50 μL / well Bright-Glo reagent was added, and the cells were shaken and lysed at room temperature for 10 minutes. Luminescence was read using an Envision microplate reader to measure luciferase activity.
[0278] The response value of 100 nM GLP-1 was set as 100% response value, and nonlinear regression was performed using GraphPad based on the response percentage and the concentration of the added compound to obtain the EC of each compound. 50 value.
[0279] 2) Agonist activity on human GIP receptor (LANCE Ultra cAMP assay)
[0280] The LANCE Ultra cAMP Kit was used to determine the agonist activity of the compounds of the present invention on human GIPR, and P001, Tirzepatide and endogenous ligand GIP were used as references.
[0281] The in vitro agonist activity of the compounds of the present invention on GIPR was determined in HEK293 cells (HEK293 / GIPR cells) stably expressing human GIPR. HEK293 / GIPR cells were prepared with HBSS buffer (0.1% Casein, 500μM IBMX, 5mM HEPES) and seeded in 384-well cell culture plates at 1000 cells / well (5μL / well). 5μL of HBSS buffer containing 2× compounds was added to the above 384-well cell culture plates. After sealing the plate, it was placed in a 5% CO2 incubator at 37°C and incubated for about 30 minutes. After the incubation was completed, 5μL of cAMP-Eu working solution and 5μL of cAMP-Ulight working solution were added in sequence, and the plate was shaken to mix. Incubate at 25°C for 1 hour, read the signal values at 665nm and 615nm on the Envision microplate reader, calculate the 665nm / 615nm ratio, and convert it into cAMP concentration using the cAMP standard curve. The response value of 1 μM GIP was set as 100% response value, and nonlinear regression was performed using GraphPad based on the response percentage and the concentration of the added compound to obtain the EC value of each compound. 50 value.
[0282] Table 2. Agonist activity at human GLP-1 and GIP receptors, EC 50 value
[0283]
[0284]
[0285] NA: Not detected
[0286] EC 50 Value: Endogenous ligand EC 50 EC 50 Value ratio
[0287] The agonist activities of all compounds on human GLP-1 and GIP receptors were expressed as EC 50 Value indicates that EC 50 The larger the value, the stronger the activity of the compound. Compared with P001, the agonist activity of the compound of the present invention on human GLP-1R and GIPR decreased to a certain extent (see Table 2).
[0288] Compared with Tirzepatide, all compounds of the present invention have stronger agonist activity on human GLP-1R than Tirzepatide, and among them, six compounds P007, P008, P013, P016, P018 and P019 also have slightly stronger agonist activity on human GIPR than Tirzepatide (see Table 2).
[0289] In summary, the compounds of the present invention with different forms of modified chains have different degrees of reduction in agonist activity on human GLP-1R and GIPR compared with P001, but 6 compounds are stronger than Tirzepatide.
[0290] In vitro functional tests showed that the activities of the 10 compounds of the present invention were not much different, so a single-dose hypoglycemic experiment in db / db mice was used to further screen the compounds.
[0291] 2. Pharmacokinetics
[0292] (A) Single-dose pharmacokinetics in SD rats
[0293] After subcutaneous or intravenous administration to SD rats, plasma was collected and its plasma drug concentration was detected to illustrate the pharmacokinetic properties of the compounds of the present invention in vivo. The compound was dissolved in phosphate buffer and filtered through a filter membrane (PTFE, 0.45 μm) to obtain a 25 nmol / mL compound solution. Male SD rats (230-268 g, n=3) were given a dose of 50.0 nmol / kg subcutaneously (sc) or 25.0 nmol / kg intravenously (iv), and about 150 μL of whole blood was collected from the internal jugular vein in an EDTA-K2 anticoagulant tube at predose, 0.0833 (iv), 0.25, 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 h, respectively. The blood sample was centrifuged at 1500 g for 10 min to obtain plasma, and the plasma was frozen at -90°C to -60°C for analysis and detection.
[0294] Sample processing
[0295] (1) Sample processing methods for Tirzepatide, P007, P008, P013, and P014
[0296] Take 30.0 μL of thawed plasma samples and add 150 μL of acetonitrile solution (containing 5 ng·mL -1 Verapamil, 50 ng·mL -1 Glyburide, 200 ng·mL -1 Tolbutamide and 200 ng·mL -1 Diclofenac) was used to precipitate protein, the mixture was vortexed for 5 min, and centrifuged at 3700 rpm for 8 min. 70.0 μL of the supernatant was taken, 70.0 μL of 0.5% formic acid aqueous solution was added, and vortexed for 5 min. 15 μL of the mixture was taken and injected into LC-MS / MS to detect the plasma drug concentration.
[0297] (2) Sample processing methods for P015, P016, P017, and P018:
[0298] Take 20.0 μL of thawed plasma samples and add 60.0 μL of acetonitrile solution (containing 5 ng·mL -1 Verapamil, 50 ng·mL -1 Glyburide, 200 ng·mL -1 Tolbutamide and 200 ng·mL -1 Diclofenac) was used to precipitate protein, the mixture was vortexed for 1 min, and centrifuged at 13000 rpm for 8 min. 60.0 μL of the supernatant was taken, 60.0 μL of 0.5% formic acid aqueous solution was added, and vortexed for 10 min. 10.0 μL of the mixture was taken and injected into LC-MS / MS to detect the plasma drug concentration.
[0299] (3) Sample processing method for P019 and P020:
[0300] Take 30.0 μL of thawed plasma samples and add 150 μL of acetonitrile solution (containing 5 ng mL -1 Verapamil, 50 ng·mL -1 Glyburide, 200 ng·mL -1 Tolbutamide and 200 ng·mL -1 Diclofenac) was used to precipitate protein, the mixture was vortexed for 5 min, and centrifuged at 3700 rpm for 8 min. 70.0 μL of the supernatant was taken, 70.0 μL of 0.5% formic acid aqueous solution was added, and vortexed for 5 min. 10.0 μL of the mixture was taken and injected into LC-MS / MS to detect the plasma drug concentration.
[0301] According to the blood concentration of the compound in SD rats, the pharmacokinetic parameters were calculated using the software Winnolin 8.2 with a non-compartmental model. The results are shown in Tables 3 and 4 below.
[0302] Table 3 Pharmacokinetic parameters of different peptide compounds after subcutaneous injection in rats
[0303]
[0304]
[0305] Table 4 Pharmacokinetic parameters of different peptide compounds after subcutaneous injection in rats
[0306]
[0307] The PK test of subcutaneous injection of the compounds of the present invention in rats showed that the half-life of P007, P008, P013, P014, P015, P016, P017, P018, and P020 was greater than that of Tirzepatide (increased by about 23.7% to 64.0%). The compounds of the present invention modified with modified chains can achieve a longer plasma half-life than Tirzepatide, a dual-target product on the market. In addition, compared with P001, the half-life of the compounds of the present invention is significantly prolonged, increasing by more than 15 times, more than 20 times, and even more than 30 times.
[0308] (II) Pharmacokinetics in C57 mice
[0309] After subcutaneous or intravenous administration to C57 mice, plasma was collected and its blood drug concentration was detected to illustrate the pharmacokinetic properties of the compounds of the present invention in vivo. The compound was dissolved in phosphate buffer containing 0.1% Tween 20 and filtered through a filter membrane (PTFE, 0.45μm) to obtain a 15nmol / mL compound solution. C57 mice (18-22g) were given a dose of 30nmol / kg subcutaneously (sc) or 15.0nmol / kg intravenously (iv), and about 100μL whole blood was collected from the eye sockets in EDTA-K2 anticoagulant tubes at predose, 0.5, 1, 2, 4, 8, 24, 48 and 72h time points, respectively. The blood sample was centrifuged at 1500g for 10min to obtain plasma, and the plasma was frozen and stored at -90°C to -60°C for analysis and detection.
[0310] Sample processing
[0311] (1) Sample processing method for Tirzepatide, P014, P016, and P020
[0312] Take 20.0 μL of thawed plasma samples and add 20 μL of 50% methanol aqueous solution (containing 100 ng mL -1 The mixture was vortexed for 5 min and centrifuged at 3700 rpm for 8 min. 50.0 μL of the supernatant was taken, 50.0 μL of 0.5% formic acid aqueous solution was added, vortexed for 5 min, and 50 μL of the mixture was taken and injected into LC-MS / MS to detect the plasma drug concentration.
[0313] According to the blood concentration of the compound in C57 mice, the pharmacokinetic parameters were calculated using the software Winnolin 8.2 with a non-compartmental model. The results are shown in Tables 5 and 6 below.
[0314] Table 5 Average pharmacokinetic parameters after single subcutaneous administration in mice
[0315]
[0316] Table 6 Average pharmacokinetic parameters after single intravenous administration in mice
[0317]
[0318] The PK test of the subcutaneous injection of the compounds of the present invention in mice showed that the half-life of P014, P016 and P020 was longer than that of Tirzepatide (increased by about 59.2% to 92.5%), and was significantly longer than that of Tirzepatide. The compounds of the present invention modified with modified chains can achieve a longer plasma half-life than Tirzepatide, a dual-target product on the market.
[0319] (III) Pharmacokinetics in cynomolgus monkeys
[0320] After subcutaneous or intravenous administration to cynomolgus monkeys, plasma was collected and its blood drug concentration was detected to clarify the pharmacokinetic properties of the compounds of the present invention in vivo. The compounds were dissolved in 1.4% PG in 8mM Na2HPO4 Buffer (pH 7.39) and filtered through a filter membrane (PTFE, 0.45μm) to obtain 25 and 12.5nmol / mL compound solutions, respectively. Cynomol / kg was administered subcutaneously (sc) or intravenously (iv) at a dose of 25 nmol / kg. At predose, 2h, 12h, 24h, 32h, 48h, 3d (72h), 4d (96h), 6d (144h), 9d (216h), 12d (288h), 15d (360h) and 18d (432h), blood was collected from the cephalic vein or other appropriate veins, and about 500 μL of whole blood was collected in an EDTA-K2 anticoagulant tube. The blood sample was centrifuged at 2200g for 10 min to obtain plasma, which was stored frozen at -90°C to -60°C for analysis and detection.
[0321] Sample processing
[0322] (1) Sample processing methods for Tirzepatide, P014, P016, P017, and P020
[0323] Take 70.0 μL of thawed plasma samples, add 70 μL of acetonitrile (containing 1 ng / ml internal standard) to precipitate protein, vortex the mixture for 1 min, and centrifuge at 14000 rpm for 10 min. Take 60.0 μL of supernatant, add 60.0 μL of 0.5% formic acid aqueous solution, vortex for 5 min, take 10 μL of the mixture, and inject LC-MS / MS to detect plasma drug concentration.
[0324] Based on the blood concentration of the compound in cynomolgus monkeys, the pharmacokinetic parameters were calculated using the software Winnolin 8.2 with a non-compartmental model. The results are shown in Tables 7 and 8 below.
[0325] Table 7 Mean pharmacokinetic parameters after single subcutaneous administration in cynomolgus monkeys
[0326]
[0327] Table 8 Mean pharmacokinetic parameters after single intravenous administration in cynomolgus monkeys
[0328]
[0329] The PK test of subcutaneous injection of the compound of the present invention in cynomolgus monkeys showed that the half-life of P014, P016 and P020 was equivalent to that of Tirzepatide, and the Tmax of P016 and P017 was delayed compared with Tirzepatide. The compound of the present invention modified with the modified chain can achieve a plasma half-life equivalent to that of Tirzepatide, a dual-target product on the market, and the Tmax of P016 and P017 is about 2 times that of Tirzepatide, and the peak time of drug concentration is significantly delayed compared with Tirzepatide, and may have milder / fewer gastrointestinal reactions, or a shorter titration time.
[0330] 3. Pharmacodynamics
[0331] (I) Pharmacodynamics in db / db mice: To study the effects of the compounds of the present invention on blood glucose in diabetic model mice (db / db mice)
[0332] In this study, a single subcutaneous administration of the compound to db / db mice was performed to detect changes in blood glucose, food intake, and body weight of the mice to clarify the hypoglycemic effect and duration of the drug effect of the compound of the present invention, and to compare with the positive controls Tirzepatide and P001. In this study, male db / db mice aged 8-9 weeks were used. The db / db mice were placed in an independent ventilation cage IVC facility with controlled temperature (20-26°C) and humidity (40-70%), controlled by a 12h:12h light / dark cycle, and free access to food and water. Blood was collected from the tip of the tail, and basal blood glucose was measured with a Roche blood glucose meter. The mice were randomly divided into groups (n=6 / group) according to the initial blood glucose and initial body weight, and each group had similar body weight and blood glucose.
[0333] The compound of the present invention (10nmol / kg) or the positive control Tirzepatide (10nmol / kg) and P001 (10nmol / kg) were dissolved in a solvent (PBS containing 0.1% Tween20, pH 7.2-7.4). After a single subcutaneous administration, the random blood glucose at the set time point (0-120h, when the random blood glucose of the compound is no different from that of the Vehicle group, the random blood glucose of the compound is stopped), as well as the daily body weight and food intake were recorded. The data results were statistically analyzed using GraphPad Prism8, and the statistical differences between the groups were analyzed using T-TEST, and P<0.05 was considered to be significant.
[0334] Duration of hypoglycemic effect: the longest time during which the random blood glucose of the compound is significantly different from that of the Vehicle group (P<0.05).
[0335] Table 9. Duration of glucose lowering effect of compounds
[0336]
[0337]
[0338] Compared with P001, the hypoglycemic effect of the compounds of the present invention lasts 24 hours or more (P007, P008, P014, P019), even more than 40 hours (P008, P014), and more than 72 hours (P014) (see Table 9, Figure 1A , Figure 1B ).
[0339] Compared with Tirzepatide, the glucose-lowering effect of the compounds of the present invention lasts equivalent to or longer (P007, P008, P013, P014, P016, P017, P018, P019, P020), and may even last for 16 hours or more (P008, P013, P014, P016, P017, P020), 24 hours or more (P013, P014, P016, P017, P020), 48 hours or more (P014, P016, P020), and 56 hours or more (P016, P020) (see Table 9).
[0340] Compared with P001: Based on the test described in the above method, during the test period, in terms of hypoglycemic efficacy, the hypoglycemic effects of P008 (p < 0.01), P014 (p < 0.001) and P019 (p < 0.05) were significantly better than those of P001 (blood glucose AUC, P < 0.05, such as Figure 2AThe blood glucose AUC inhibition rates were 2.3, 2.6 and 2.2 times that of P001, respectively; the duration of blood glucose reduction was 40h, 72h and 24h longer than that of P001, respectively (Table 9). The blood glucose reduction effect of P007 was equivalent to that of P001, but the duration of blood glucose reduction was 24h longer than that of P001 (as shown in Table 9). Figure 2A , as shown in Table 9).
[0341] Compared with Tirzepatide: Compared with Tirzepatide, P014 (p < 0.05, Figure 2B ), P016(p<0.05, Figure 2C ) and P020 (p<0.05, Figure 2C ) had a stronger hypoglycemic effect (blood glucose AUC, p < 0.05), and the blood glucose AUC inhibition rates were 1.7, 2.2, and 2.0 times that of Tirzepatide, respectively; moreover, they also showed a significantly longer duration of drug effect (48h, 56h, and 56h longer than Tirzepatide, respectively, Table 9). The hypoglycemic effects of P013 and P017 were comparable to those of Tirzepatide ( Figure 2C ), but the duration of efficacy was 24 h longer than that of Tirzepatide (Table 9).
[0342] Unexpectedly, compared with P001, the acylated GLP-1 / GIP agonist of the present invention significantly improves the hypoglycemic effect while achieving a long-lasting effect. The compounds of the present invention with different forms of modified chains can achieve a stronger and more lasting hypoglycemic effect than P001, and some of the compounds of the present invention show a stronger and more lasting hypoglycemic effect than Tirzepatide.
[0343] In addition, based on the target binding and agonist activity of the compounds of the present invention on human GLP-1 and GIP receptors, it was unexpectedly found that the target binding and agonist activity of the compounds of the present invention on human GLP-1 receptors were significantly reduced compared with P001, and the target binding and agonist activity of the compounds of the present invention on human GIP receptors were also significantly reduced, but the hypoglycemic effect of the compounds of the present invention was significantly better than that of P001.
[0344] (II) Multiple-dose experiment in db / db mice
[0345] In this study, the compound of the present invention was subcutaneously administered to db / db mice multiple times, and the changes in blood glucose of the mice were detected to further illustrate the hypoglycemic effect of the compound of the present invention, and compared with the positive control Tirzepatide. In this study, male db / db mice aged 7-8 weeks were used. The db / db mice were placed in an IVC facility with controlled temperature (20-26°C) and humidity (40-70%), controlled by a 12h:12h light / dark cycle, and free access to food and water. Blood was collected from the tip of the tail, and basal blood glucose was measured with a Roche blood glucose meter. The mice were randomly divided into groups (n=6 / group) according to the initial blood glucose and initial body weight, and each group had similar body weight and blood glucose.
[0346] The compound of the present invention (3, 10, 30 nmol / kg) or the positive control Tirzepatide (3, 10, 30 nmol / kg) was dissolved in a solvent (PBS containing 0.1% Tween20, pH 7.2-7.4). The drug was administered by subcutaneous injection once every 3 days for four weeks. Subcutaneous injection was performed on days 1, 4, 7, 10, 13, 16, 19, 22 and 25. Random blood glucose was recorded every 3 days throughout the study. Fasting blood glucose was tested on day 28, and then blood was collected by orbital bleeding. After orbital bleeding, the animals were killed and the liver was removed and weighed. The collected blood was centrifuged at 3000 rpm for 10 minutes after 1 to 2 hours to separate the serum. Biochemical indicators such as triglyceride (TG), alanine aminotransferase (ALT), and total bilirubin (TBIL) were detected using a biochemical analyzer. The data results were statistically analyzed using GraphPad Prism8, and T-TEST was used to analyze the statistical differences between the groups. P < 0.05 was considered to be significant.
[0347] In the experiments conducted as described above, the compounds of the present invention, such as P014, P016, P017 and P020, all showed better blood glucose suppression than Tirzepatide at a dose of 3 nmol / kg; at a dose of 30 nmol / kg, the efficacy of P016 was superior to that of Tirzepatide (see Figures 3A-3D , Table 10). P016, P017 and P020 can significantly reduce the liver weight of db / db mice at multiple doses, while Tirzepatide does not reduce the liver weight at three experimental doses. The compounds of the present invention, such as P014, P016, P017, P020 and Tirzepatide, can effectively reduce the serum TG of db / db mice (except for the P017 and Tirzepatide 3nmol / kg groups), and the efficacy of some dose groups of P016 and P020 is better than that of Tirzepatide (see Table 11). In addition, P014 and P016 can also reduce serum TBIL and / or ALT.
[0348] Table 10. Fasting blood glucose and blood glucose AUC of db / db mice
[0349]
[0350] T-Test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with vehicle group; #p<0.05, ##p<0.01, ###p<0.001 compared with Tirzepatide (TZP) same dose group. The results are expressed as Mean±SEM of 6 mice.
[0351] Table 11. Liver weight and serum TG of db / db mice
[0352]
[0353] T-Test, *p<0.05, **p<0.01, ***p<0.001 compared with vehicle group; #p<0.05, ##p<0.01 compared with
[0354] Tirzepatide (TPZ) was compared with the same dose group. The results are expressed as Mean ± SEM of 6 mice.
[0355] Table 12. Serum ALT and TBIL of db / db mice
[0356]
[0357] T-Test, *p<0.05 compared with vehicle group; #p<0.05, ##p<0.01 compared with Tirzepatide (TPZ) same dose group. The results are expressed as Mean±SEM of 6 mice.
[0358] In summary, under this experimental system, the compounds of the present invention can effectively reduce the blood sugar of db / db mice by subcutaneous injection for 4 weeks, and the effective dose (≤3nmol / kg) is 1 / 3 of Tirzepatide (10nmol / kg), and the maximum efficacy (30nmol / kg) of some compounds of the present invention, such as P016, is stronger than Tirzepatide. In addition, some compounds of the present invention show a reduction in liver weight and a protective effect on the liver of db / db mice, while Tirzepatide has no similar effect.
[0359] (III) Repeated administration of drugs to male rats for 2 weeks
[0360] 1. Experimental Design
[0361] 77 SD male rats (SPF grade) were selected and randomly divided into 10 groups according to body weight. Group 1 was the vehicle control group, with 5 animals; Groups 2 to 4 were the commercially available drug control group (Tirzepatide), with 8 animals in each group, including 5 animals in the main test and 3 animals in the toxicity test, and the dosages were 1, 3, and 10 mg / kg respectively; Groups 5 to 7 were the test substance group 1, and groups 8 to 10 were the test substance group 2, with 8 animals in each group, including 5 animals in the main test and 3 animals in the toxicity test, and the dosages were 1, 3, and 10 mg / kg respectively. All the above groups were administered twice a week for 2 consecutive weeks (administration days were: D1, 5, 8, 12, and 15).
[0362] During the experiment, cage and tray observation, detailed clinical observation, food consumption measurement, body weight measurement, blood biochemistry and hematological index measurement, gross anatomical observation, organ weighing, and toxicokinetics study were performed on all groups of animals.
[0363] 2. Statistics
[0364] The following table details the combinations used for statistical comparisons. See the table below:
[0365] Statistical methods table
[0366]
[0367] Raw data for each time period will be tabulated, and the mean and standard deviation / or category change will be calculated by group and gender for each endpoint. For each endpoint, the treatment group will be compared to the control group as described below. Endpoint data will be log-transformed before specific analysis as required.
[0368] Statistical analysis table
[0369]
[0370] 3. Experimental results
[0371] Body weight / weight gain: After the first dose, weight loss was observed in the following dose groups in each dosing group: Tirzepatide ≥ 3 mg / kg; P014 and P016 ≥ 1 mg / kg. As the dosing continued, body weight recovered to some extent. By the end of the dosing, body weight in all groups was increasing, but the weight gain was less than that in the control group, showing a clear dose-related relationship.
[0372] Food intake: A dose-related decrease in food intake was observed in all treatment groups (Tirzepatide, P014 and P016) throughout the entire test. Blood biochemistry: Amylase and triglyceride levels decreased. Hematology: Reticulocyte levels were slightly decreased. Gross autopsy: No abnormalities were found in any of the treatment groups (Tirzepatide, P014 and P016). Organ weight: The weight of the heart, liver, spleen, etc. in each treatment group (Tirzepatide, P014 and P016) was reduced, with little difference compared with the vehicle control group, which may be related to weight loss and is considered to be related to pharmacological effects. Toxicokinetics: C in the Tirzepatide, P014, and P016 groups max Both the AUC and the PUC increased with dose in a dose-proportional manner. The drug was given twice a week for 2 consecutive weeks, and no obvious accumulation was observed in the TZP, P014, and P016 dose groups.
[0373] Each dosing group (Tirzepatide, P014 and P016) was given twice a week, and the MTD of continuous administration for 2 weeks was ≥10 mg / kg, corresponding to the C max and AUC last And the test safety window results are as follows:
[0374] Table 13. Safety window of each dosing group
[0375]
[0376] In summary, the toxicity properties of P016 and P014 are similar to those of Tirzepatide, but they have a higher safety window (calculated by exposure, the safety window of P014 is more than 4 times that of Tirzepatide, while the safety window of P016 is more than 7 times that of Tirzepatide.
[0377] In addition, relative to the safety window of P001, the safety window of the compounds of the present invention is 10 times, or 20 times, or 30 times, or 40 times, or 50 times, or 60 times, or 70 times, or 80 times, or 90 times larger than that of P001, especially P014 and P016.
[0378] At the same time, at the same exposure dose, the effect of the compound of the present invention on HR is lower than that of Tirepatide, the heart rate increase of P016 is lower than that of Tirepatide, and there is no sustained heart rate increase of more than 30%. At the same exposure dose, the heart rate recovery of P016 is faster than that of TZP (the recovery time of P016 is between 72 and 120 hours, and the recovery time of TZP is greater than 120 hours).
[0379] The peptide compounds and applications provided by the present invention are introduced in detail above.
[0380] The principles and implementation methods of the present invention are described in this article using specific embodiments. The description of the above embodiments is only used to help understand the method and the central idea of the present invention. It should be pointed out that for ordinary technicians in this field, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the protection of the claims of the present invention.
[0381] Amino Acid Sequence:
[0382]
[0383]
Claims
1. A compound of the following formula (AI), or a pharmaceutically acceptable salt thereof: Y-X1-EGT-X2-TSDY-A11-A12-A13-LDK-A17-AQ-A20-EFVKWLLK-A29-GPSSGAPPPSK (AI); in, X1 is Aib; X2 is αMePhe; A11 is Aib; A12 is Ile; A13 is Aib; A17 is Gln; A20 is Ala; A29 is Gly, Select one of the K positions at position 24 and position 28, and use ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -Z is chemically modified by conjugating to the ε-amino group of the K side chain, wherein each a is independently selected from an integer of 1, 2, and 3, each b is independently selected from an integer of 1, 2, and 3, each c is independently selected from an integer of 16, 18, and 20, wherein Z is independently selected from -CH3, carboxylic acid; and the C-terminal amino acid is amidated to form a C-terminal primary amide.
2. The compound according to claim 1, wherein At position 24, K is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain for chemical modification; or At position 28, K is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H was conjugated to the ε-amino group of the K side chain for chemical modification.
3. The compound according to claim 1 or 2, wherein At position 24, K is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu) b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain for chemical modification, wherein each a is independently selected from an integer of 2 or 3, each b is independently 1, and each c is independently selected from an integer of 16, 18, or 20, wherein Z is independently selected from a carboxylic acid.
4. The compound according to claim 1 or 2, wherein At position 28, K is replaced by ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(γ-Glu)b -CO-(CH2) c -CO2H is conjugated to the ε-amino group of the K side chain for chemical modification, wherein each a is independently selected from an integer of 2 or 3, each b is independently selected from an integer of 1 or 3, each c is independently selected from an integer of 16 or 20, and Z is independently selected from a carboxylic acid.
5. The compound according to claim 1 or 2, wherein the compound is K at position 24 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 7); or K at position 24 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 18 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 13); or K at position 24 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 14); or K at position 24 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 15); or K at position 24 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 16); or K at position 28 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 16 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 8); or K at position 28 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)1-CO-(CH2) 20 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 17); or K at position 28 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)3-CO-(CH2) 16 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 18); or K at position 28 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 16 -CO2H is conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid is amidated to a C-terminal primary amide (SEQ ID NO: 19); or K at position 28 is synthesized by using ([2-(2-amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)1-CO-(CH2) 20 -CO2H was conjugated to the ε-amino group of the K side chain and chemically modified; and the C-terminal amino acid was amidated to a C-terminal primary amide (SEQ ID NO: 20).
6. The compound according to claim 5, wherein the compound is or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier, diluent or excipient.
8. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or the composition according to claim 7, in the preparation of a medicament for treating or preventing the following diseases: the diseases are hyperglycemia, impaired glucose tolerance, type I diabetes, type II diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease and other cardiovascular diseases, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcer.
9. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or the composition according to claim 7, in the preparation of a medicament for delaying or preventing the progression of type II diabetes.
10. Use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or a composition according to claim 7, in the preparation of a medicament for reducing food intake, reducing β-cell apoptosis, increasing β-cell function and β-cell mass, and / or restoring β-cell glucose sensitivity.
